$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000142072022000064 Filed on October 11, 2022

Income Statement

Concept	2022 Q4	2022 Q2	2022
Revenue	$0.00	$61.00K	$2.383M
YoY Change	-100.0%	-87.58%	0.51%
Cost Of Revenue		$15.00K	$216.0K
YoY Change		-91.98%	-85.23%
Gross Profit		$46.00K	$2.167M
YoY Change		-84.87%	138.39%
Gross Profit Margin		75.41%	90.94%
Selling, General & Admin	$7.229M	$8.846M	$32.37M
YoY Change	-13.55%	33.1%	48.89%
% of Gross Profit		19230.43%	1493.68%
Research & Development	$2.779M	$6.336M	$17.73M
YoY Change	-16.57%	104.59%	77.49%
% of Gross Profit		13773.91%	818.14%
Depreciation & Amortization	$241.0K	$823.0K	$2.275M
YoY Change	-53.38%	30.63%	-5.76%
% of Gross Profit		1789.13%	104.98%
Operating Expenses	$10.57M	$15.18M	$51.86M
YoY Change	-9.58%	55.82%	61.95%
Operating Profit	-$10.57M	-$15.14M	-$49.69M
YoY Change	-9.15%	60.36%	59.72%
Interest Expense	$31.00K	-$158.0K	$1.412M
YoY Change	-90.55%	-75.91%	-161.02%
% of Operating Profit
Other Income/Expense, Net	$10.00K	$0.00	-$614.0K
YoY Change	-103.55%	-100.0%	-106.01%
Pretax Income	-$10.56M	-$17.05M	-$50.30M
YoY Change	-11.38%	-15059.65%	116.71%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$33.55M	-$17.05M	-$50.30M
YoY Change	181.48%	-14801.72%	116.76%
Net Earnings / Revenue		-27957.38%	-2110.91%
Basic Earnings Per Share	-$3.42		-$5.78
Diluted Earnings Per Share	-$3.42	-$1.954M	-$5.78
COMMON SHARES
Basic Shares Outstanding	9.007M	218.2M	8.721M
Diluted Shares Outstanding	9.807M		8.721M

Balance Sheet

Concept	2022 Q4	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.625M	$33.52M	$33.52M
YoY Change	-83.22%	-65.43%	-65.43%
Cash & Equivalents	$3.696M	$22.68M	$22.68M
Short-Term Investments	$5.929M	$10.85M	$10.85M
Other Short-Term Assets	$20.87M	$1.549M	$1.549M
YoY Change	614.27%	-25.17%	-25.17%
Inventory		$3.900M	$3.900M
Prepaid Expenses
Receivables	$970.0K	$1.000M	$1.000M
Other Receivables	$6.769M	$5.100M	$5.100M
Total Short-Term Assets	$38.24M	$45.07M	$45.07M
YoY Change	-43.35%	-56.91%	-56.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.245M	$36.66M	$41.76M
YoY Change	-87.09%	324.91%	20.2%
Goodwill
YoY Change
Intangibles	$5.398M	$4.851M
YoY Change	7.08%	409.56%
Long-Term Investments
YoY Change
Other Assets	$303.0K	$6.099M	$6.099M
YoY Change	-95.78%	25312.5%	25312.5%
Total Long-Term Assets	$13.57M	$54.34M	$54.34M
YoY Change	-76.99%	28.24%	28.24%
TOTAL ASSETS
Total Short-Term Assets	$38.24M	$45.07M	$45.07M
Total Long-Term Assets	$13.57M	$54.34M	$54.34M
Total Assets	$51.80M	$99.41M	$99.41M
YoY Change	-59.03%	-32.36%	-32.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.002M	$4.264M	$4.264M
YoY Change	46.11%	89.17%	89.17%
Accrued Expenses	$5.001M	$3.764M	$3.865M
YoY Change	75.97%	25.42%	28.79%
Deferred Revenue		$100.0K
YoY Change
Short-Term Debt	$16.01M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due	$411.0K	$22.21M	$22.21M
YoY Change	813.33%	5950.95%	5950.95%
Total Short-Term Liabilities	$27.78M	$30.44M	$30.44M
YoY Change	232.79%	358.03%	358.03%
LONG-TERM LIABILITIES
Long-Term Debt	$1.878M	$30.00K	$30.00K
YoY Change	-91.5%	-99.91%	-99.91%
Other Long-Term Liabilities	$3.324M	$5.455M	$5.455M
YoY Change	-38.44%
Total Long-Term Liabilities	$5.202M	$5.485M	$5.485M
YoY Change	-81.09%	-82.73%	-82.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.78M	$30.44M	$30.44M
Total Long-Term Liabilities	$5.202M	$5.485M	$5.485M
Total Liabilities	$32.98M	$35.92M	$35.92M
YoY Change	-8.01%	-6.46%	-6.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$275.6M	-$223.9M
YoY Change	41.71%	28.97%
Common Stock	$294.6M	$287.6M
YoY Change	3.31%	1.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.82M	$63.49M	$63.49M
YoY Change
Total Liabilities & Shareholders Equity	$51.80M	$99.41M	$99.41M
YoY Change	-59.03%	-32.36%	-32.36%

Cashflow Statement

Concept	2022 Q4	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$33.55M	-$17.05M	-$50.30M
YoY Change	181.48%	-14801.72%	116.76%
Depreciation, Depletion And Amortization	$241.0K	$823.0K	$2.275M
YoY Change	-53.38%	30.63%	-5.76%
Cash From Operating Activities	-$7.635M	-$11.50M	-$37.48M
YoY Change	-28.55%	59.19%	24.67%
INVESTING ACTIVITIES
Capital Expenditures	$2.954M	-$3.430M	$7.330M
YoY Change	-238.49%	34.25%	-242.0%
Acquisitions
YoY Change
Other Investing Activities	$1.699M	$3.907M	$6.503M
YoY Change	46.34%	-1206.8%	-130.51%
Cash From Investing Activities	-$1.255M	$477.0K	-$5.127M
YoY Change	29.12%	-116.4%	-80.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.044M	-10.00K	-6.125M
YoY Change	-49.41%	-100.34%	-107.77%
NET CHANGE
Cash From Operating Activities	-7.635M	-11.50M	-37.48M
Cash From Investing Activities	-1.255M	477.0K	-5.127M
Cash From Financing Activities	-3.044M	-10.00K	-6.125M
Net Change In Cash	-11.93M	-11.04M	-48.73M
YoY Change	-32.48%	52.81%	-318.6%
FREE CASH FLOW
Cash From Operating Activities	-$7.635M	-$11.50M	-$37.48M
Capital Expenditures	$2.954M	-$3.430M	$7.330M
Free Cash Flow	-$10.59M	-$8.073M	-$44.81M
YoY Change	23.8%	72.83%	79.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8721000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7825000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.78
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.00
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Lease Practical Expedients Package LeasePracticalExpedientsPackage	true
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.78
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.00
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8721000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7825000
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2022Q2	us-gaap	Assets Assets	99406000
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8727158
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8714924
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35023
CY2022	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2797813
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	8800 HSC Parkway
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Bryan
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77807-1107
CY2022	dei	City Area Code CityAreaCode	302
CY2022	dei	Local Phone Number LocalPhoneNumber	355-0650
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	IBIO
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	119731492
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9006583
CY2022	dei	Auditor Firm AuditorFirmId	596
CY2022	dei	Auditor Name AuditorName	CohnReznick LLP
CY2022	dei	Auditor Location AuditorLocation	Holmdel, New Jersey
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22676000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77404000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	426000
CY2022Q2	us-gaap	Settlement Assets Current SettlementAssetsCurrent	5100000
CY2021Q2	us-gaap	Settlement Assets Current SettlementAssetsCurrent	5100000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2021Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	19570000
CY2022Q2	us-gaap	Inventory Net InventoryNet	3900000
CY2021Q2	us-gaap	Inventory Net InventoryNet	27000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1549000
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2070000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	45070000
CY2021Q2	us-gaap	Assets Current AssetsCurrent	104597000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5996000
CY2022Q2	ibio	Convertible Promissory Note Receivable And Accrued Interest ConvertiblePromissoryNoteReceivableAndAccruedInterest	1631000
CY2021Q2	ibio	Convertible Promissory Note Receivable And Accrued Interest ConvertiblePromissoryNoteReceivableAndAccruedInterest	1556000
CY2021Q2	ibio	Settlement Assets Non Current SettlementAssetsNonCurrent	5100000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	74000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	26111000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5020000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36661000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8628000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	952000
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	74000
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	29000
CY2021Q2	us-gaap	Security Deposit SecurityDeposit	24000
CY2022Q2	us-gaap	Assets Assets	99406000
CY2021Q2	us-gaap	Assets Assets	146968000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4264000
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2254000
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	701000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3764000
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3001000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46000
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	367000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101000
CY2021Q2	ibio	Paycheck Protection Program Note Payable Current Portion PaycheckProtectionProgramNotePayableCurrentPortion	600000
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	22161000
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	423000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	30436000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6645000
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	30000
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31755000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5455000
CY2022Q2	us-gaap	Liabilities Liabilities	35921000
CY2021Q2	us-gaap	Liabilities Liabilities	38400000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8727158
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8714924
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	9000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	9000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	287619000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	282266000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-213000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-63000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223930000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173627000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	63485000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	108585000
CY2021Q2	us-gaap	Minority Interest MinorityInterest	-17000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63485000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	108568000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99406000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	146968000
CY2022	us-gaap	Revenues Revenues	2383000
CY2021	us-gaap	Revenues Revenues	2371000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	216000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1462000
CY2022	us-gaap	Gross Profit GrossProfit	2167000
CY2021	us-gaap	Gross Profit GrossProfit	909000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17729000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9989000
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	250000
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	1587000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34128000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22031000
CY2022	us-gaap	Operating Expenses OperatingExpenses	51857000
CY2021	us-gaap	Operating Expenses OperatingExpenses	32020000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-49690000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-31111000
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	810000
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2446000
CY2022	us-gaap	Interest Expense InterestExpense	1412000
CY2021	us-gaap	Interest Expense InterestExpense	2454000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	178000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	140000
CY2022	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	7000
CY2021	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	12000
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	10200000
CY2022	ibio	Forgiveness Of Note Payable And Accrued Interest Sba Loan ForgivenessOfNotePayableAndAccruedInterestSbaLoan	607000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-614000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7898000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2021	us-gaap	Profit Loss ProfitLoss	-23213000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-50303000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23207000
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	260000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50391000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23467000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2021	us-gaap	Profit Loss ProfitLoss	-23213000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-150000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-29000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-50454000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-23243000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.78
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.00
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8721000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7825000
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	56607000
CY2021	ibio	Stock Issued During Period Value Capital Raise StockIssuedDuringPeriodValueCapitalRaise	78276000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4713000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1586000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-29000
CY2021	us-gaap	Profit Loss ProfitLoss	-23213000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	108568000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	967000
CY2022	ibio	Adjustments To Additional Paid In Capital Acquisition Of Remaining Portion Of Affiliate AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate	50000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4377000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-150000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63485000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2021	us-gaap	Profit Loss ProfitLoss	-23213000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4377000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1586000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	401000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	291000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	599000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1651000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	516000
CY2022	us-gaap	Depreciation Depreciation	2275000
CY2021	us-gaap	Depreciation Depreciation	472000
CY2022	ibio	Accrued Interest Receivable On Convertible Promissory Note Receivable AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable	75000
CY2021	ibio	Accrued Interest Receivable On Convertible Promissory Note Receivable AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable	56000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	312000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	216000
CY2021	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-143000
CY2022	ibio	Deferred Financing Costs Amortization Expense DeferredFinancingCostsAmortizationExpense	107000
CY2022	ibio	Forgiveness Of Note Payable And Accrued Interest Sba Loan ForgivenessOfNotePayableAndAccruedInterestSbaLoan	607000
CY2022	ibio	Settlement Of Revenue Contract SettlementOfRevenueContract	84000
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	1760000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	886000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	426000
CY2021	ibio	Increase Decrease In Accounts Receivable Other IncreaseDecreaseInAccountsReceivableOther	112000
CY2022	ibio	Increase Decrease In Settlement Assets IncreaseDecreaseInSettlementAssets	-5100000
CY2021	ibio	Increase Decrease In Settlement Assets IncreaseDecreaseInSettlementAssets	10200000
CY2022	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	3873000
CY2021	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	-772000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-307000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1746000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	74000
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-5000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1239000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	48000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1443000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1897000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-15000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1387000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37480000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30064000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5355000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	23816000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13618000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4000000
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	1760000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4300000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	242000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7330000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4920000
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1500000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5127000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26478000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5830000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	331000
CY2021	ibio	Proceeds From Issuance Of Preferred And Common Stock ProceedsFromIssuanceOfPreferredAndCommonStock	78276000
CY2021	ibio	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	5549000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54000
CY2022	ibio	Payments To Attain Term Note PaymentsToAttainTermNote	322000
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3896000
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	50000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4713000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6125000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78835000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48732000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22292000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77404000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55112000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28672000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77404000
CY2022	ibio	Non Cash Transaction Increase In Right Of Use Assets And Liabilities NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities	5570000
CY2021	ibio	Non Cash Transaction Increase In Right Of Use Assets And Liabilities NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities	146000
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	29000
CY2022	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	791000
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	150000
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	29000
CY2022	ibio	Lease Incentive For Construction In Progress LeaseIncentiveForConstructionInProgress	82000
CY2022	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	1769000
CY2021	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	791000
CY2022	ibio	Termination Of Finance Lease Right Of Use Asset Including Issuance Of Warrant TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant	25386000
CY2022	us-gaap	Notes Issued1 NotesIssued1	22375000
CY2022	ibio	Non Cash Settlement Of Revenue Contract NonCashSettlementOfRevenueContract	580000
CY2022	ibio	Warrants Issued For Finance Lease Payment WarrantsIssuedForFinanceLeasePayment	217000
CY2022	ibio	Noncash Or Part Noncash Acquisition Non Controlling Interest Assumed NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed	18000
CY2021	ibio	Legal Costs Related To Litigation LegalCostsRelatedToLitigation	16000000
CY2021	ibio	Legal Cost Recovery Related To Litigation LegalCostRecoveryRelatedToLitigation	16000000
CY2021	ibio	Accounts Receivable And Accounts Payable Offset Related To Legal Settlement AccountsReceivableAndAccountsPayableOffsetRelatedToLegalSettlement	75000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1045000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2446000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1. </b><b style="font-weight:bold;">Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (“we”, “us”, “our”, “iBio”, “iBio, Inc” or the “Company”) is a developer of next-generation biopharmaceuticals using our proprietary Artificial Intelligence (“AI”)-Driven Discovery Platform and FastPharming<sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">®</sup><i style="font-style:italic;"> </i>Manufacturing System. We are focusing our technologies on the research and development of novel products at its Drug Discovery Center in California. We are currently using our <i style="font-style:italic;">FastPharming</i> Manufacturing System (“<i style="font-style:italic;">FastPharming</i>” or the “<i style="font-style:italic;">FastPharming</i> System”) and <i style="font-style:italic;">Glycaneering</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Technologies to develop our portfolio of proprietary biologic drug candidates. We also offer contract development and manufacturing services from its 130,000 square foot cGMP facility in Texas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We operate in two segments: (i) <b style="font-weight:bold;">Biopharmaceuticals;</b> its large molecule discovery, development, and licensing activities, and (ii) <b style="font-weight:bold;">Bioprocessing</b>; its contract development and manufacturing services for recombinant proteins. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On September 19, 2022<span style="font-size:11pt;">, </span>we acquired substantially all of the assets of RubrYc Therapeutics, Inc. (“RubrYc”) which included<b style="font-weight:bold;">:</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:17.85pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Drug Discovery Platform</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: A patented system that uses artificial intelligence (“AI”) to design 3D models of subdominant and conformational epitopes to facilitate the creation of antibody drug candidates against previously hard-to-target tumors. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:17.85pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Previously Licensed Candidates</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: All rights, with no future milestone payments or royalty obligations, to IBIO-101, an IL-2 sparing anti-CD25 antibody for depletion of regulatory T cells, along with the jointly discovered monoclonal antibody (“Target 6”) that was identified in Q2 FY2022 using the Discovery Engine.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Therapeutic Candidates</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Three immuno-oncology candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We expect the addition of new therapeutic candidates and an AI-driven drug discovery platform for difficult to treat tumors to strengthen its Biopharmaceutical discovery and development capabilities. Meanwhile, IBIO-101 remains our lead immuno-oncology asset. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20220630x10k001.jpg" style="display:inline-block;height:220.55pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">For our Bioprocessing area, the <i style="font-style:italic;">FastPharming</i> System is our proprietary approach to recombinant protein production using plants. It uses hydroponically grown <i style="font-style:italic;">Nicotiana benthamiana (</i>a relative of the tobacco plant), novel expression vectors, and transient transfection at scale to produce complex proteins emerging from our own development pipeline or for our clients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In an effort to focus our resources on the promising new AI discovery platform and entering the clinic with our lead compounds, we have initiated a review of potential options to accelerate our transformation into a platform drug discovery </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">and development company while extending our cash runway. These include a review of the pipeline, asset sales or licenses, partnerships, portfolio decisions, cost reductions, and efforts to raise additional capital, including non-dilutive additions of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"></span></p>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2022Q2	ibio	Number Of Affiliates With Non Controlling Interests NumberOfAffiliatesWithNonControllingInterests	2
CY2022Q2	ibio	Cash And Cash Equivalents Plus Debt Securities CashAndCashEquivalentsPlusDebtSecurities	39500000
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	4000
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	27000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property including impairment considerations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p>
CY2022	ibio	Number Of Lines Of Business NumberOfLinesOfBusiness	3
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022	us-gaap	Revenues Revenues	2383000
CY2021	us-gaap	Revenues Revenues	2371000
CY2021Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2022Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	423000
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	178000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1087000
CY2022Q2	ibio	Percentage Of Collateral Required PercentageOfCollateralRequired	0.05
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5996000
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22676000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77404000
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	28672000
CY2021Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	77404000
CY2022Q2	us-gaap	Inventory Net InventoryNet	3900000
CY2021Q2	us-gaap	Inventory Net InventoryNet	27000
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	33000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Depreciation Depreciation	472000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains principally all cash balances in one financial institution which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2022 and 2021, amounts in excess of insured limits were approximately $18,200,000 and $27,013,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, the Company generated 100% of its revenue from 10 customers with one customer accounting for 76% of revenue related to a licensing agreement (see Note 20 – Fraunhofer Settlement). During the year ended June 30, 2021, the Company generated 99% of its revenue from four customers, each of whom individually accounted for more than 10% of revenue.</p>
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	18200000
CY2021Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	27013000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2021Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	19570000
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	497000
CY2021Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	7500000
CY2021Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	7500000
CY2021Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.07606
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11029000
CY2021Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19603000
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	8054000
CY2021Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	11430000
CY2022Q2	ibio	Available For Sale Securities Debt Maturities With In Two Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost	2791000
CY2021Q2	ibio	Available For Sale Securities Debt Maturities With In Two Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost	8140000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2021Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	19570000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	312000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	216000
CY2022Q2	ibio	Finance Lease Right Of Use Asset Gross FinanceLeaseRightOfUseAssetGross	146000
CY2021Q2	ibio	Finance Lease Right Of Use Asset Gross FinanceLeaseRightOfUseAssetGross	33635000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	72000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	7524000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	74000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	26111000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	599000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1651000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1225000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36661000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8628000
CY2022	us-gaap	Depreciation Depreciation	2275000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	11383
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3603000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1967000
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	59000
CY2021Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	295000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5020000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40161000
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9853000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3500000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5946000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5820000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5270000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4868000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	676000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	952000
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4175000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	952000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	401000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	291000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	261000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	165000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	69000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	57000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	45000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	79000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	676000
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31755000
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M3D
CY2021Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P28Y6M29D
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0625
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3066000
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1667000
CY2022Q2	ibio	Accrued Real Estate Taxes AccruedRealEstateTaxes	284000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	126000
CY2021Q2	ibio	Accrued Interest Current AccruedInterestCurrent	406000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	229000
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	136000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3764000
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3001000
CY2022	ibio	Notes Payable Ppp Loan Disclosure Textblock NotesPayablePppLoanDisclosureTextblock	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Notes Payable – PPP Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-weight:normal;">On April 16, 2020, the Company received </span><span style="font-weight:normal;">$600,000</span><span style="font-weight:normal;"> related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). </span><span style="font-weight:normal;">The Company elected to treat the Small Business Administration (“SBA”) Loan as debt under ASC 470, </span><i style="font-style:italic;font-weight:normal;">Debt</i><span style="font-weight:normal;">. At June 30, 2021, the Company owned </span><span style="font-weight:normal;">$600,000</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. In accordance with ASC 405-20-40, <i style="font-style:italic;">Liabilities - Extinguishments of Liabilities – Derecognition</i>, the Company derecognized the liability and accrued interest in the first quarter of Fiscal 2022. </p>
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	600000
CY2021Q2	ibio	Lessor Finance Lease Monthly Rent LessorFinanceLeaseMonthlyRent	3819
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	599000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1651000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	816000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2447000
CY2022	ibio	Lease Cost Due To Increase In Consumer Price Index LeaseCostDueToIncreaseInConsumerPriceIndex	64000
CY2021	ibio	Lease Cost Due To Increase In Consumer Price Index LeaseCostDueToIncreaseInConsumerPriceIndex	200000
CY2022	us-gaap	Lease Cost LeaseCost	1479000
CY2021	us-gaap	Lease Cost LeaseCost	4298000
CY2022	ibio	Operating Lease Payments Consumer Price Index OperatingLeasePaymentsConsumerPriceIndex	64000
CY2021	ibio	Operating Lease Payments Consumer Price Index OperatingLeasePaymentsConsumerPriceIndex	200000
CY2022	ibio	Financing Cash Flows From Finance Lease Obligation FinancingCashFlowsFromFinanceLeaseObligation	5830000
CY2021	ibio	Financing Cash Flows From Finance Lease Obligation FinancingCashFlowsFromFinanceLeaseObligation	331000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	74000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	26111000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46000
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	367000
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	30000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	101000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year One LesseeOperatingLeaseImputedInterestToBePaidYearOne	359000
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year One LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne	460000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	400000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Two LesseeOperatingLeaseImputedInterestToBePaidYearTwo	382000
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Two LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo	782000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	448000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Three LesseeOperatingLeaseImputedInterestToBePaidYearThree	352000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	50000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	31000
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	81000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	11383
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P88M
CY2021Q3	ibio	Lessee Operating Lease Monthly Rent LesseeOperatingLeaseMonthlyRent	51223
CY2021Q3	ibio	Lessee Operating Lease Annual Percentage Increase In Base Rent LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent	0.03
CY2021Q3	us-gaap	Tenant Improvements TenantImprovements	81860
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	555000
CY2022	ibio	Total Operating Lease Costs TotalOperatingLeaseCosts	555000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	555000
CY2022	ibio	Operating Cash Flows From Operating Lease Obligation OperatingCashFlowsFromOperatingLeaseObligation	15000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5020000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5455000
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P23Y7M20D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	209600
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	36.00
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2147
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	25.50
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Three LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree	800000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	503000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Four LesseeOperatingLeaseImputedInterestToBePaidYearFour	317000
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Four LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour	820000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	560000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Five LesseeOperatingLeaseImputedInterestToBePaidYearFive	279000
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Five LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive	839000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3544000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid After Year Five LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive	3217000
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid After Year Five LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive	6761000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5556000
CY2022Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Total LesseeOperatingLeaseImputedInterestToBePaidTotal	4906000
CY2022Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest	10462000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5455000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3380
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2147
	ibio	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1162807
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6400000
	ibio	Stock Issued During Period Shares Cashless Exercise Of Warrants StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants	237193
	ibio	Cashless Exercise Of Warrants Reducing Balance Owed For Notes Payable CashlessExerciseOfWarrantsReducingBalanceOwedForNotesPayable	1300000
	ibio	Adjustments To Additional Paid In Capital Class Of Warrant Or Right Expense Recognized AdjustmentsToAdditionalPaidInCapitalClassOfWarrantOrRightExpenseRecognized	313000
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4798
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	61.25
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-50303000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23207000
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	260000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50391000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23467000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8721000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7825000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.78
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.00
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	694000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	369000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4377000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1586000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	139031
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.50
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4042000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	341686
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1995000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	340814
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	32.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1988000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	77338
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	890000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	341686
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1995000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	313568
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.50
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3380
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	30068
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	35.00
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	621806
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	197404
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	30.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	620810
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	29.25
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	621806
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	28.31
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	197404
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3334000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	911000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	165000
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9962000
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2022Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	71000
CY2021Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	91000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	145000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	38000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36765000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	23.25
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	31.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0080
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0252
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0039
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0102
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1916
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2034
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1946
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2655
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q2	us-gaap	Share Price SharePrice	6.50
CY2021Q2	us-gaap	Share Price SharePrice	37.75
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2021	us-gaap	Profit Loss ProfitLoss	-23213000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27714000
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2008Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5500000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9051000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-55000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-9051000
CY2021	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-55000
CY2022	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	9051000
CY2021	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	55000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35829000
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24693000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1248000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	353000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1764000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1737000
CY2022Q2	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	370000
CY2021Q2	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	0
CY2022Q2	us-gaap	Deferred Tax Asset Parents Basis In Discontinued Operation DeferredTaxAssetParentsBasisInDiscontinuedOperation	0
CY2021Q2	us-gaap	Deferred Tax Asset Parents Basis In Discontinued Operation DeferredTaxAssetParentsBasisInDiscontinuedOperation	984000
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2520000
CY2021Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	170500000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	63900000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	106600000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.03
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.18
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	319000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	121000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2022	us-gaap	Revenues Revenues	2383000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	216000
CY2022	us-gaap	Gross Profit GrossProfit	2167000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17729000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34128000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-49690000
CY2022	us-gaap	Interest Expense InterestExpense	1412000
CY2022	ibio	Forgiveness Of Note Payable And Accrued Interest Sba Loan ForgivenessOfNotePayableAndAccruedInterestSbaLoan	607000
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	191000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	74000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5020000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36661000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	599000
CY2022	us-gaap	Depreciation Depreciation	2275000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	401000
CY2021	us-gaap	Revenues Revenues	2371000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1462000
CY2021	us-gaap	Gross Profit GrossProfit	909000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9989000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22031000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-31111000
CY2021	us-gaap	Interest Expense InterestExpense	2454000
CY2021	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	10200000
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	152000
CY2021	us-gaap	Profit Loss ProfitLoss	-23213000
CY2021Q2	us-gaap	Assets Assets	146968000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	26111000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8628000
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	952000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1651000
CY2021	us-gaap	Depreciation Depreciation	472000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	291000

Files In Submission

Name	View Source	Status
0001420720-22-000064-index-headers.html	Edgar Link	pending
0001420720-22-000064-index.html	Edgar Link	pending
0001420720-22-000064.txt	Edgar Link	pending
0001420720-22-000064-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibio-20220630.xsd	Edgar Link	pending
ibio-20220630x10k.htm	Edgar Link	pending
ibio-20220630x10k001.jpg	Edgar Link	pending
ibio-20220630x10k002.jpg	Edgar Link	pending
ibio-20220630x10k003.jpg	Edgar Link	pending
ibio-20220630xex10d51.htm	Edgar Link	pending
ibio-20220630xex21d1.htm	Edgar Link	pending
ibio-20220630xex23d1.htm	Edgar Link	pending
ibio-20220630xex31d1.htm	Edgar Link	pending
ibio-20220630xex31d2.htm	Edgar Link	pending
ibio-20220630xex32d1.htm	Edgar Link	pending
ibio-20220630xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ibio-20220630_cal.xml	Edgar Link	unprocessable
ibio-20220630_def.xml	Edgar Link	unprocessable
ibio-20220630_pre.xml	Edgar Link	unprocessable
ibio-20220630_lab.xml	Edgar Link	unprocessable
ibio-20220630x10k_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2022 Q4 Form 10-K Financial Statement

#000142072022000064 Filed on October 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2022 Q4 Form 10-K Financial Statement

#000142072022000064 Filed on October 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio